1. Inicio
  2. Publicaciones
  3. Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase ? trial.

Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase ? trial.

Fecha de publicación: Fecha Ahead of Print:

Autores de I3PT

Participantes ajenos a I3PT

  • Pérez-García JM
  • Llombart-Cussac A
  • G Cortés M
  • Curigliano G
  • López-Miranda E
  • Alonso JL
  • Bermejo B
  • Calvo L
  • Carañana V
  • de la Cruz Sánchez S
  • M Vázquez R
  • Prat A
  • R Borrego M
  • Sampayo-Cordero M
  • Soberino J
  • Malfettone A
  • Schmid P
  • Cortés J

Grupos de Investigación

Abstract

Pembrolizumab has modest activity if used in patients with hormone-receptor-positive (HR+), HER2-negative, previously treated metastatic breast cancer (BC). Our study investigated whether there would be any clinical benefit in combining chemotherapy with pembrolizumab in a similar patient population.

Datos de la publicación

ISSN/ISSNe:
0959-8049, 1879-0852

EUROPEAN JOURNAL OF CANCER  ELSEVIER SCI LTD

Tipo:
Article
Páginas:
382-394
PubMed:
33794440

Citas Recibidas en Web of Science: 33

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Eribulin, HR-positive/HER2-negative metastatic breast cancer, PD-L1, Pembrolizumab

Campos de Estudio

Compartir